Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review

Overview

Journal J Vitreoretin Dis

Publisher Sage Publications

Date 2023 Apr 3

PMID 37008395

Authors

Patrick Wang

Zoe Hu

Maggie Hou

Patrick A Norman

Eric K Chin

David Rp Almeida

Affiliations

Soon will be listed here.

Abstract

Purpose: To examine the relationship between central macular thickness (CMT) measured by optical coherence tomography (OCT) and visual acuity (VA) in patients with center-involving diabetic macular edema (DME) receiving antivascular endothelial growth factor (anti-VEGF) treatment.

Methods: Peer-reviewed articles from 2016 to 2020 reporting intravitreal injections of bevacizumab, ranibizumab, or aflibercept that provided data on pretreatment (baseline) and final retinal thickness (CMT) and visual acuity (VA) were identified. The relationship between relative changes was assessed via a linear random-effects regression model controlling for treatment group.

Results: No significant association between the logarithm of the minimum angle of resolution (logMAR) VA and CMT was found in 41 eligible studies evaluating 2667 eyes. The observed effect estimate was a 0.12 increase (95% CI, -0.124 to 2.47) in logMAR VA per 100 µm reduction in CMT after treatment change. There were no significant differences in logMAR VA between the anti-VEGF treatment groups.

Conclusions: There was no statistically significant relationship between the change in logMAR VA and change in CMT as well as no significant effect of the type of anti-VEGF treatment on the change in logMAR VA. Although OCT analysis, including measurements of CMT, will continue to be an integral part of the management of DME, further exploration is needed on additional anatomic factors that might contribute to visual outcomes.

Citing Articles

Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema.

Mishra S, Kumar P, Joshi A, Saraf A, Awasthi A, Dhar S Int J Retina Vitreous. 2025; 11(1):6.

PMID: 39806501 PMC: 11727401. DOI: 10.1186/s40942-025-00628-x.

Diabetic Disease of the Eye in Canada: Consensus Statements from a Retina Specialist Working Group.

Omar A, Williams R, Whelan J, Noble J, Brent M, Giunta M Ophthalmol Ther. 2024; 13(5):1071-1102.

PMID: 38526804 PMC: 11039592. DOI: 10.1007/s40123-024-00923-0.

References

Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M . Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008; 28(8):1053-60. DOI: 10.1097/IAE.0b013e318176de48. View

Kook P, Maier M, Schuster T, Feucht N, Lohmann C . Nine-month results of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular oedema: a retrospective analysis. Acta Ophthalmol. 2011; 89(8):769-73. DOI: 10.1111/j.1755-3768.2009.01823.x. View

Bek T, Jorgensen C . The Systemic Blood Pressure and Oxygen Saturation in Retinal Arterioles Predict the Effect of Intravitreal Anti-VEGF Treatment on Diabetic Maculopathy. Invest Ophthalmol Vis Sci. 2016; 57(13):5429-5434. DOI: 10.1167/iovs.16-20305. View

Bressler S, Glassman A, Almukhtar T, Bressler N, Ferris F, Googe Jr J . Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. Am J Ophthalmol. 2016; 164:57-68. PMC: 4811755. DOI: 10.1016/j.ajo.2015.12.025. View

Otani T, Yamaguchi Y, Kishi S . Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina. 2009; 30(5):774-80. DOI: 10.1097/IAE.0b013e3181c2e0d6. View

Vyas S, Thapa R, Bajimaya S, Pradhan E, Paudyal G . Anatomical and visual outcome of intravitreal bevacizumab (Avastin) in patients with diabetic macular edema. Nepal J Ophthalmol. 2017; 8(15):54-61. DOI: 10.3126/nepjoph.v8i1.16157. View

Rahimy E, Shahlaee A, Khan M, Ying G, Maguire J, Ho A . Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema. Am J Ophthalmol. 2016; 164:118-27.e2. DOI: 10.1016/j.ajo.2015.12.030. View

Sugar E, Jabs D, Altaweel M, Lightman S, Acharya N, Vitale A . Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol. 2011; 152(6):1044-1052.e5. PMC: 3223264. DOI: 10.1016/j.ajo.2011.05.028. View

Seo J, Park I . Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol. 2009; 23(1):17-22. PMC: 2655742. DOI: 10.3341/kjo.2009.23.1.17. View

10.

Laugesen C, Ostri C, Brynskov T, Lund-Andersen H, Larsen M, Vorum H . Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes. Acta Ophthalmol. 2016; 95(1):28-32. DOI: 10.1111/aos.13160. View

11.

Faghihi H, Roohipoor R, Mohammadi S, Hojat-Jalali K, Mirshahi A, Lashay A . Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008; 18(6):941-8. DOI: 10.1177/112067210801800614. View

12.

Chung H, Park B, Shin H, Kim H . Correlation of fundus autofluorescence with spectral-domain optical coherence tomography and vision in diabetic macular edema. Ophthalmology. 2012; 119(5):1056-65. DOI: 10.1016/j.ophtha.2011.11.018. View

13.

Bong A, Doughty M, Button N, Mansfield D . On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review. Clin Exp Optom. 2016; 99(6):491-497. DOI: 10.1111/cxo.12393. View

14.

Fang X, Sakaguchi H, Gomi F, Oshima Y, Sawa M, Tsujikawa M . Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol. 2008; 86(7):800-5. DOI: 10.1111/j.1755-3768.2008.01254.x. View

15.

Warid Al-Laftah F, Elshafie M, Alhashimi M, Pai A, Farouq M . Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema. Saudi J Ophthalmol. 2013; 24(4):133-8. PMC: 3729384. DOI: 10.1016/j.sjopt.2010.05.001. View

16.

Bhagat N, Grigorian R, Tutela A, Zarbin M . Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009; 54(1):1-32. DOI: 10.1016/j.survophthal.2008.10.001. View

17.

Browning D, Glassman A, Aiello L, Beck R, Brown D, Fong D . Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2006; 114(3):525-36. PMC: 2585542. DOI: 10.1016/j.ophtha.2006.06.052. View

18.

Kaiho T, Oshitari T, Tatsumi T, Takatsuna Y, Arai M, Shimizu N . Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol. Biomed Res Int. 2018; 2017:7879691. PMC: 5733831. DOI: 10.1155/2017/7879691. View

19.

Chen Y, Chang P, Wang J . Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept. Asia Pac J Ophthalmol (Phila). 2017; 6(3):250-255. DOI: 10.22608/APO.2016186. View

20.

Seo K, Yu S, Kim M, Kwak H . VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS. Retina. 2015; 36(3):588-95. DOI: 10.1097/IAE.0000000000000770. View